

April 18, 2019

To: The Office of the Attorney General of Vermont

Via: Electronic Mail (AGO.DrugCosts@vermont.gov; AGO.highcostprescriptiondrugs@vermont.gov)

Re: Notice of New Drug Introduction Pursuant to 18 V.S.A. § 4637 (b)

Amgen Inc, USA (Amgen) hereby submits this information pursuant 18 V.S.A § 4637 (b):

On April 15, 2019 Amgen released the following specialty drug to the commercial market:

| Name of New Prescription Drug | NDC Number | Date of Commercial Availability | WAC |
|--|---------------|---------------------------------|---------|
| Evenity 210 mg/2.34 mL (105 mg/1.17 mL x 2) | 55513-0880-02 | April 15, 2019 | \$1,825 |

Amgen provides this report consistent with its understanding and interpretation of 18 V.S.A § 4637 and its provisions. In providing this report, Amgen does not waive any rights it may have at law or in equity with respect to 18 V.S.A. § 4637, its interpretation, and/or its application to Teva or any of its affiliates, now or in the future. Amgen, on behalf of itself and its affiliates, expressly reserves all such rights.

Regards,



Kave Niksefat

VP, US Value and Access

Amgen Inc, USA